Published in Cancer Res on April 04, 2011
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A (2014) 1.25
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol (2011) 0.90
Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo. Oncotarget (2016) 0.82
Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol (2014) 0.80
Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv (2013) 0.80
Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem. Childs Nerv Syst (2014) 0.76
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv (2015) 0.76
Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg (2016) 0.76
Convection-Enhanced Delivery. Neurotherapeutics (2017) 0.75
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res (1989) 4.01
NG2-expressing glial progenitor cells: an abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci (2003) 3.69
Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res (1988) 3.26
Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res (1996) 2.67
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res (1990) 2.49
Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci (2006) 2.43
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery (2008) 2.33
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res (1989) 1.94
Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter. J Neurosci (1999) 1.68
Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci (2005) 1.65
NG2 proteoglycan-expressing cells of the adult rat brain: possible involvement in the formation of glial scar astrocytes following stab wound. Glia (2005) 1.52
Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay. J Neurooncol (1992) 1.47
Defining the NG2-expressing cell of the adult CNS. J Neurocytol (2003) 1.38
Heterogeneity of cycling glial progenitors in the adult mammalian cortex and white matter. J Neurobiol (2001) 1.36
Action of camptothecin on mammalian cells in culture. Cancer Res (1972) 1.24
PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain. Glia (2009) 1.24
Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res (1990) 1.23
Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol (1996) 1.20
A2B5+ and O4+ Cycling progenitors in the adult forebrain white matter respond differentially to PDGF-AA, FGF-2, and IGF-1. Mol Cell Neurosci (2002) 1.14
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res (1988) 1.13
Astrocytes and oligodendrocytes can be generated from NG2+ progenitors after acute brain injury: intracellular localization of oligodendrocyte transcription factor 2 is associated with their fate choice. Eur J Neurosci (2009) 1.13
Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery (2000) 1.08
Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem (1994) 1.05
Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol (1990) 1.03
Clinical pharmacokinetics of topotecan. Clin Pharmacokinet (1996) 1.03
PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. Int J Cancer (2009) 1.03
Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res (1992) 1.00
Convection-enhanced delivery in the treatment of malignant glioma. Neurol Res (2006) 1.00
Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia (2009) 0.96
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol Pharmacol (2007) 0.94
Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. Cancer Res (2005) 0.93
Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. J Pharmacol Exp Ther (2009) 0.88
Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res (1974) 0.83
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature (2009) 5.48
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (2007) 3.70
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 2.86
Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci (2006) 2.43
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery (2008) 2.33
The role of myosin II in glioma invasion of the brain. Mol Biol Cell (2008) 2.20
The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg (2013) 2.01
Neural systems subserving valence and arousal during the experience of induced emotions. Emotion (2010) 1.97
Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia (2006) 1.83
Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther (2007) 1.80
Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One (2011) 1.77
Delayed surgical resection of central nervous system germ cell tumors. Neurosurgery (2002) 1.57
Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol (2009) 1.56
Ultra-high-field MR imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.52
Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis (2011) 1.49
The neurophysiological bases of emotion: An fMRI study of the affective circumplex using emotion-denoting words. Hum Brain Mapp (2009) 1.44
Epithelioid pituicytoma. World Neurosurg (2011) 1.39
Astrocyte elevated gene-1: a novel target for human glioma therapy. Mol Cancer Ther (2010) 1.39
Constitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matter. J Neurosci (2008) 1.38
Astrocytic regulation of human monocytic/microglial activation. J Immunol (2008) 1.32
An affective circumplex model of neural systems subserving valence, arousal, and cognitive overlay during the appraisal of emotional faces. Neuropsychologia (2008) 1.32
Correction of eddy-current distortions in diffusion tensor images using the known directions and strengths of diffusion gradients. J Magn Reson Imaging (2006) 1.31
Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol (2004) 1.30
Behavioral aspects of Lesch-Nyhan disease and its variants. Dev Med Child Neurol (2005) 1.29
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25
Magnetic resonance imaging characteristics of glioblastoma multiforme: implications for understanding glioma ontogeny. Neurosurgery (2010) 1.19
Primitive neuroectodermal tumors of the spine: a comprehensive review with illustrative clinical cases. Neurosurg Focus (2011) 1.18
A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS One (2012) 1.15
Metastases to the pineal gland. Neurology (2006) 1.15
Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery (2011) 1.14
Glial progenitors in the brainstem give rise to malignant gliomas by platelet-derived growth factor stimulation. Glia (2010) 1.14
Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res (2006) 1.12
Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) (2009) 1.11
The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J Immunol (2009) 1.11
Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol (2009) 1.11
Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary (2008) 1.11
Effect of static magnetic field exposure of up to 8 Tesla on sequential human vital sign measurements. J Magn Reson Imaging (2003) 1.08
Meningiomas of the velum interpositum: surgical considerations. Neurosurg Focus (2003) 1.07
Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab (2008) 1.07
A review of malignant meningiomas: diagnosis, characteristics, and treatment. J Neurooncol (2010) 1.02
The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn (2012) 1.02
Preferential in situ CD4+CD56+ T cell activation and expansion within human glioblastoma. J Immunol (2008) 1.01
Approaches to anterior and anterolateral foramen magnum lesions: A critical review. J Craniovertebr Junction Spine (2010) 1.00
Convection-enhanced delivery in the treatment of malignant glioma. Neurol Res (2006) 1.00
Tumor-associated macrophages in glioma: friend or foe? J Oncol (2013) 1.00
Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J Neurooncol (2010) 0.99
A statistical framework for the classification of tensor morphologies in diffusion tensor images. Magn Reson Imaging (2006) 0.98
Interactions between the L1 cell adhesion molecule and ezrin support traction-force generation and can be regulated by tyrosine phosphorylation. J Neurosci Res (2008) 0.98
Surgical management of craniopharyngiomas. J Neurooncol (2009) 0.98
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary (2011) 0.98
Motor deficits correlate with resting state motor network connectivity in patients with brain tumours. Brain (2012) 0.97
Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. Mol Biol Cell (2012) 0.97
Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery (2006) 0.95
Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. Clin Immunol (2002) 0.95
An fMRI study of the brain responses of traumatized mothers to viewing their toddlers during separation and play. Soc Cogn Affect Neurosci (2011) 0.95
Simultaneous above and below approach to giant pituitary adenomas: surgical strategies and long-term follow-up. Pituitary (2009) 0.94
Multimodal magnetic resonance imaging: The coordinated use of multiple, mutually informative probes to understand brain structure and function. Hum Brain Mapp (2011) 0.94
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? Neuro Oncol (2011) 0.94
Incidence, cost, and mortality associated with hospital-acquired conditions after resection of cranial neoplasms. Neurosurgery (2014) 0.94
A virtual reality-based FMRI study of reward-based spatial learning. Neuropsychologia (2010) 0.93
Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery (2007) 0.93
E2F1 coregulates cell cycle genes and chromatin components during the transition of oligodendrocyte progenitors from proliferation to differentiation. J Neurosci (2014) 0.92
Design and performance issues of RF coils utilized in ultra high field MRI: experimental and numerical evaluations. IEEE Trans Biomed Eng (2005) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
Expression patterns of LIS1, dynein and their interaction partners dynactin, NudE, NudEL and NudC in human gliomas suggest roles in invasion and proliferation. Acta Neuropathol (2007) 0.91
Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly. Pituitary (2003) 0.91
Murine cell line model of proneural glioma for evaluation of anti-tumor therapies. J Neurooncol (2013) 0.91
Cytochrome c oxidase deficiency due to a novel SCO2 mutation mimics Werdnig-Hoffmann disease. Arch Neurol (2002) 0.91
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol (2011) 0.90
Pre-operative intracranial meningioma embolization. Expert Rev Neurother (2011) 0.90
MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet (2012) 0.90
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma. Neurol Res (2012) 0.90
Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue. J Neurooncol (2007) 0.89
Evoked potential monitoring identifies possible neurological injury during positioning for craniotomy. Anesth Analg (2009) 0.88
Medulloblasoma: challenges for effective immunotherapy. J Neurooncol (2011) 0.88
MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol (2013) 0.88
Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients. J Neurooncol (2009) 0.88